NICE recommends Galapagos filgotinib on NHS for rheumatoid arthritis

 

• NICE guidance, for the first time in the UK, supports access to an advanced therapy for people with moderate as well as severe rheumatoid arthritis (RA) - aiming to avoid irreversible damage as early as possible¹
• More than 400,000 people across the UK live with RA² and around 70% have moderate or severe disease³

https://www.globenewswire.com/news-release/2021/01/21/2161865/0/en/NICE-recommends-Jyseleca-filgotinib-on-NHS-in-landmark-decision-for-rheumatoid-arthritis.html